Global Pediatric Clinical Trials Market

Pediatric Clinical Trials Comprehensive Study by Type (Phase I, Phase II, Phase III, Phase IV), Application (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, Others), Study Design (Interventional (Randomized Trial) Players and Region - Global Market Outlook to 2030

Pediatric Clinical Trials Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pediatric Clinical Trials
Clinical trials typically test a specific involvement which may be a drug, medical device, or procedure-- following a research protocol developed by an investigator. Children and adolescents upto 18 years as their bodies’ physiology and chemistry react very differently to illness and disease. Thus, pediatric clinical trials are critical to developing treatments and medications for childhood disease and illnesses. The number of paediatric clinical trials in EU has remarkably increased in the last decade in response to the execution of the new Paediatric Regulation and enticements aiming to define the need of child-specific drug development.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Pediatric Clinical Trials market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bristol-Myers Squibb Company (United States), Charles River Laboratories International Inc. (United States), Covance Inc. (United States), GlaxoSmithKline plc (United Kingdom), ICON plc (Ireland), IQVIA (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States), Pharmaceutical Product Development, LLC (United States), Syneos Health Inc. (United States), Parexel (United States), Duke Clinical Research Institute (United States), Syneos Health (United States), PRA Health Sciences (United States) and Chiltern (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Paidion Research, Inc. (United States) and Medpace (United States).

Segmentation Overview
AMA Research has segmented the market of Global Pediatric Clinical Trials market by Type (Phase I, Phase II, Phase III and Phase IV), Application (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes and Others) and Region.



On the basis of geography, the market of Pediatric Clinical Trials has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Study Design, the sub-segment i.e. Interventional [Randomized Trial will boost the Pediatric Clinical Trials market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Implementation of Clinical Trials by Pharmaceutical Companies on Their Own Premises

Market Growth Drivers:
Growing Awareness about Pediatric Medicine and Rising Burden of Pediatric Diseases, Such as Diabetes

Challenges:
The Gap between the Number of Paediatric and Adult-Randomised Controlled Trials

Opportunities:
Shifting From In-House Clinical Research to Contract Research Organization (CRO) and Increasing Research Practices in Pharmaceutical Companies

Market Leaders and their expansionary development strategies
March 2022 - Pfizer started Phase 2/3 research in March 2022 for PAXLOVID pills, which are intended to treat COVID-19 in young patients. Within three days of the onset of symptoms, PAXLOVID decreased the probability of hospitalisation or mortality from any cause by 89% and 88%, respectively (within five days of appearance of symptoms).
March 2022 - As the first of numerous significant enhancements to its leading life science customer engagement platform, IQVIA had announced the launch of OCE+. With the addition of IQVIA's Next Best recommendation engine to its Orchestrated Customer Engagement (OCE) platform, OCE+ provides enhanced HCP experiences, higher efficiency, and increased ROI for healthcare professionals (HCPs).
The FDA released an update to the nearly two-decades old harmonized guidelines on clinical investigations in pediatric patients (originally adopted by the FDA in December 2000). The updated guidance for industry, E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population, was issued by the FDA on April 11, 2018. Evidence for pediatric efficacy and safety is required by the FDA under the Pediatric Research Equity Act (PREA) in certain drug applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration. and In the European Union, paediatric clinical trials are conducted under the 2007 Paediatric Regulation. This act provides the legal framework for safe research on children, ensuring that studies are high quality, ethically researched, and fully authorised.

Key Target Audience
Pediatric Clinical Trials Providers, Pharmaceutical Industry, Clinical Research Institutes, Regulatory Bodies and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
By Application
  • Respiratory Diseases
  • Infectious Diseases
  • Oncology
  • Diabetes
  • Others
By Study Design
  • Interventional [Randomized Trial

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Awareness about Pediatric Medicine
      • 3.2.2. Rising Burden of Pediatric Diseases, Such as Diabetes
    • 3.3. Market Challenges
      • 3.3.1. The Gap between the Number of Paediatric and Adult-Randomised Controlled Trials
    • 3.4. Market Trends
      • 3.4.1. Implementation of Clinical Trials by Pharmaceutical Companies on Their Own Premises
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pediatric Clinical Trials, by Type, Application, Study Design and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Pediatric Clinical Trials (Value)
      • 5.2.1. Global Pediatric Clinical Trials by: Type (Value)
        • 5.2.1.1. Phase I
        • 5.2.1.2. Phase II
        • 5.2.1.3. Phase III
        • 5.2.1.4. Phase IV
      • 5.2.2. Global Pediatric Clinical Trials by: Application (Value)
        • 5.2.2.1. Respiratory Diseases
        • 5.2.2.2. Infectious Diseases
        • 5.2.2.3. Oncology
        • 5.2.2.4. Diabetes
        • 5.2.2.5. Others
      • 5.2.3. Global Pediatric Clinical Trials by: Study Design (Value)
        • 5.2.3.1. Interventional [Randomized Trial
      • 5.2.4. Global Pediatric Clinical Trials Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Pediatric Clinical Trials (Price)
      • 5.3.1. Global Pediatric Clinical Trials by: Type (Price)
  • 6. Pediatric Clinical Trials: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Charles River Laboratories International Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Covance Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ICON plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. IQVIA (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pharmaceutical Product Development, LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Syneos Health Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Parexel (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Duke Clinical Research Institute (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Syneos Health (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. PRA Health Sciences (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Chiltern (United Kingdom)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Pediatric Clinical Trials Sale, by Type, Application, Study Design and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Pediatric Clinical Trials (Value)
      • 7.2.1. Global Pediatric Clinical Trials by: Type (Value)
        • 7.2.1.1. Phase I
        • 7.2.1.2. Phase II
        • 7.2.1.3. Phase III
        • 7.2.1.4. Phase IV
      • 7.2.2. Global Pediatric Clinical Trials by: Application (Value)
        • 7.2.2.1. Respiratory Diseases
        • 7.2.2.2. Infectious Diseases
        • 7.2.2.3. Oncology
        • 7.2.2.4. Diabetes
        • 7.2.2.5. Others
      • 7.2.3. Global Pediatric Clinical Trials by: Study Design (Value)
        • 7.2.3.1. Interventional [Randomized Trial
      • 7.2.4. Global Pediatric Clinical Trials Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Pediatric Clinical Trials (Price)
      • 7.3.1. Global Pediatric Clinical Trials by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pediatric Clinical Trials: by Type(USD Million)
  • Table 2. Pediatric Clinical Trials Phase I , by Region USD Million (2018-2023)
  • Table 3. Pediatric Clinical Trials Phase II , by Region USD Million (2018-2023)
  • Table 4. Pediatric Clinical Trials Phase III , by Region USD Million (2018-2023)
  • Table 5. Pediatric Clinical Trials Phase IV , by Region USD Million (2018-2023)
  • Table 6. Pediatric Clinical Trials: by Application(USD Million)
  • Table 7. Pediatric Clinical Trials Respiratory Diseases , by Region USD Million (2018-2023)
  • Table 8. Pediatric Clinical Trials Infectious Diseases , by Region USD Million (2018-2023)
  • Table 9. Pediatric Clinical Trials Oncology , by Region USD Million (2018-2023)
  • Table 10. Pediatric Clinical Trials Diabetes , by Region USD Million (2018-2023)
  • Table 11. Pediatric Clinical Trials Others , by Region USD Million (2018-2023)
  • Table 12. Pediatric Clinical Trials: by Study Design(USD Million)
  • Table 13. Pediatric Clinical Trials Interventional [Randomized Trial , by Region USD Million (2018-2023)
  • Table 14. South America Pediatric Clinical Trials, by Country USD Million (2018-2023)
  • Table 15. South America Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 16. South America Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 17. South America Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 18. Brazil Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 19. Brazil Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 20. Brazil Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 21. Argentina Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 22. Argentina Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 23. Argentina Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 24. Rest of South America Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 27. Asia Pacific Pediatric Clinical Trials, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 31. China Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 32. China Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 33. China Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 34. Japan Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 35. Japan Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 36. Japan Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 37. India Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 38. India Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 39. India Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 40. South Korea Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 41. South Korea Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 42. South Korea Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 43. Taiwan Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 44. Taiwan Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 45. Taiwan Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 46. Australia Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 47. Australia Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 48. Australia Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 52. Europe Pediatric Clinical Trials, by Country USD Million (2018-2023)
  • Table 53. Europe Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 54. Europe Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 55. Europe Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 56. Germany Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 57. Germany Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 58. Germany Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 59. France Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 60. France Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 61. France Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 62. Italy Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 63. Italy Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 64. Italy Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 65. United Kingdom Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 68. Netherlands Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 69. Netherlands Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 70. Netherlands Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 71. Rest of Europe Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 74. MEA Pediatric Clinical Trials, by Country USD Million (2018-2023)
  • Table 75. MEA Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 76. MEA Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 77. MEA Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 78. Middle East Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 79. Middle East Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 80. Middle East Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 81. Africa Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 82. Africa Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 83. Africa Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 84. North America Pediatric Clinical Trials, by Country USD Million (2018-2023)
  • Table 85. North America Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 86. North America Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 87. North America Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 88. United States Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 89. United States Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 90. United States Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 91. Canada Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 92. Canada Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 93. Canada Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 94. Mexico Pediatric Clinical Trials, by Type USD Million (2018-2023)
  • Table 95. Mexico Pediatric Clinical Trials, by Application USD Million (2018-2023)
  • Table 96. Mexico Pediatric Clinical Trials, by Study Design USD Million (2018-2023)
  • Table 97. Pediatric Clinical Trials: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Pediatric Clinical Trials: by Type(USD Million)
  • Table 114. Pediatric Clinical Trials Phase I , by Region USD Million (2025-2030)
  • Table 115. Pediatric Clinical Trials Phase II , by Region USD Million (2025-2030)
  • Table 116. Pediatric Clinical Trials Phase III , by Region USD Million (2025-2030)
  • Table 117. Pediatric Clinical Trials Phase IV , by Region USD Million (2025-2030)
  • Table 118. Pediatric Clinical Trials: by Application(USD Million)
  • Table 119. Pediatric Clinical Trials Respiratory Diseases , by Region USD Million (2025-2030)
  • Table 120. Pediatric Clinical Trials Infectious Diseases , by Region USD Million (2025-2030)
  • Table 121. Pediatric Clinical Trials Oncology , by Region USD Million (2025-2030)
  • Table 122. Pediatric Clinical Trials Diabetes , by Region USD Million (2025-2030)
  • Table 123. Pediatric Clinical Trials Others , by Region USD Million (2025-2030)
  • Table 124. Pediatric Clinical Trials: by Study Design(USD Million)
  • Table 125. Pediatric Clinical Trials Interventional [Randomized Trial , by Region USD Million (2025-2030)
  • Table 126. South America Pediatric Clinical Trials, by Country USD Million (2025-2030)
  • Table 127. South America Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 128. South America Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 129. South America Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 130. Brazil Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 131. Brazil Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 132. Brazil Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 133. Argentina Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 134. Argentina Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 135. Argentina Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 136. Rest of South America Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 137. Rest of South America Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 138. Rest of South America Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 139. Asia Pacific Pediatric Clinical Trials, by Country USD Million (2025-2030)
  • Table 140. Asia Pacific Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 141. Asia Pacific Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 142. Asia Pacific Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 143. China Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 144. China Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 145. China Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 146. Japan Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 147. Japan Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 148. Japan Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 149. India Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 150. India Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 151. India Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 152. South Korea Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 153. South Korea Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 154. South Korea Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 155. Taiwan Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 156. Taiwan Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 157. Taiwan Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 158. Australia Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 159. Australia Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 160. Australia Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 164. Europe Pediatric Clinical Trials, by Country USD Million (2025-2030)
  • Table 165. Europe Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 166. Europe Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 167. Europe Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 168. Germany Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 169. Germany Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 170. Germany Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 171. France Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 172. France Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 173. France Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 174. Italy Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 175. Italy Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 176. Italy Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 177. United Kingdom Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 178. United Kingdom Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 179. United Kingdom Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 180. Netherlands Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 181. Netherlands Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 182. Netherlands Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 183. Rest of Europe Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 184. Rest of Europe Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 185. Rest of Europe Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 186. MEA Pediatric Clinical Trials, by Country USD Million (2025-2030)
  • Table 187. MEA Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 188. MEA Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 189. MEA Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 190. Middle East Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 191. Middle East Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 192. Middle East Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 193. Africa Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 194. Africa Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 195. Africa Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 196. North America Pediatric Clinical Trials, by Country USD Million (2025-2030)
  • Table 197. North America Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 198. North America Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 199. North America Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 200. United States Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 201. United States Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 202. United States Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 203. Canada Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 204. Canada Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 205. Canada Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 206. Mexico Pediatric Clinical Trials, by Type USD Million (2025-2030)
  • Table 207. Mexico Pediatric Clinical Trials, by Application USD Million (2025-2030)
  • Table 208. Mexico Pediatric Clinical Trials, by Study Design USD Million (2025-2030)
  • Table 209. Pediatric Clinical Trials: by Type(USD/Units)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pediatric Clinical Trials: by Type USD Million (2018-2023)
  • Figure 5. Global Pediatric Clinical Trials: by Application USD Million (2018-2023)
  • Figure 6. Global Pediatric Clinical Trials: by Study Design USD Million (2018-2023)
  • Figure 7. South America Pediatric Clinical Trials Share (%), by Country
  • Figure 8. Asia Pacific Pediatric Clinical Trials Share (%), by Country
  • Figure 9. Europe Pediatric Clinical Trials Share (%), by Country
  • Figure 10. MEA Pediatric Clinical Trials Share (%), by Country
  • Figure 11. North America Pediatric Clinical Trials Share (%), by Country
  • Figure 12. Global Pediatric Clinical Trials: by Type USD/Units (2018-2023)
  • Figure 13. Global Pediatric Clinical Trials share by Players 2023 (%)
  • Figure 14. Global Pediatric Clinical Trials share by Players (Top 3) 2023(%)
  • Figure 15. Global Pediatric Clinical Trials share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 19. Charles River Laboratories International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Charles River Laboratories International Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Covance Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Covance Inc. (United States) Revenue: by Geography 2023
  • Figure 23. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 25. ICON plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. ICON plc (Ireland) Revenue: by Geography 2023
  • Figure 27. IQVIA (United States) Revenue, Net Income and Gross profit
  • Figure 28. IQVIA (United States) Revenue: by Geography 2023
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 31. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Pharmaceutical Product Development, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pharmaceutical Product Development, LLC (United States) Revenue: by Geography 2023
  • Figure 35. Syneos Health Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Syneos Health Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Parexel (United States) Revenue, Net Income and Gross profit
  • Figure 38. Parexel (United States) Revenue: by Geography 2023
  • Figure 39. Duke Clinical Research Institute (United States) Revenue, Net Income and Gross profit
  • Figure 40. Duke Clinical Research Institute (United States) Revenue: by Geography 2023
  • Figure 41. Syneos Health (United States) Revenue, Net Income and Gross profit
  • Figure 42. Syneos Health (United States) Revenue: by Geography 2023
  • Figure 43. PRA Health Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 44. PRA Health Sciences (United States) Revenue: by Geography 2023
  • Figure 45. Chiltern (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. Chiltern (United Kingdom) Revenue: by Geography 2023
  • Figure 47. Global Pediatric Clinical Trials: by Type USD Million (2025-2030)
  • Figure 48. Global Pediatric Clinical Trials: by Application USD Million (2025-2030)
  • Figure 49. Global Pediatric Clinical Trials: by Study Design USD Million (2025-2030)
  • Figure 50. South America Pediatric Clinical Trials Share (%), by Country
  • Figure 51. Asia Pacific Pediatric Clinical Trials Share (%), by Country
  • Figure 52. Europe Pediatric Clinical Trials Share (%), by Country
  • Figure 53. MEA Pediatric Clinical Trials Share (%), by Country
  • Figure 54. North America Pediatric Clinical Trials Share (%), by Country
  • Figure 55. Global Pediatric Clinical Trials: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb Company (United States)
  • Charles River Laboratories International Inc. (United States)
  • Covance Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • ICON plc (Ireland)
  • IQVIA (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
  • Pharmaceutical Product Development, LLC (United States)
  • Syneos Health Inc. (United States)
  • Parexel (United States)
  • Duke Clinical Research Institute (United States)
  • Syneos Health (United States)
  • PRA Health Sciences (United States)
  • Chiltern (United Kingdom)
Additional players considered in the study are as follows:
Paidion Research, Inc. (United States) , Medpace (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 221 Pages 94 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pediatric Clinical Trials Market Quantitative research analysis
Global Pediatric Clinical Trials Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bristol-Myers Squibb Company (United States), Charles River Laboratories International Inc. (United States), Covance Inc. (United States), GlaxoSmithKline plc (United Kingdom), ICON plc (Ireland), IQVIA (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States), Pharmaceutical Product Development, LLC (United States), Syneos Health Inc. (United States), Parexel (United States), Duke Clinical Research Institute (United States), Syneos Health (United States), PRA Health Sciences (United States) and Chiltern (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Implementation of Clinical Trials by Pharmaceutical Companies on Their Own Premises" is seen as one of major influencing trends for Pediatric Clinical Trials Market during projected period 2023-2030.
The Pediatric Clinical Trials market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Pediatric Clinical Trials Market Report?

Have a Query? Click Here

Other Related Reports

Dry Skin Treatment Comprehensive Study by Type (Moisturizer (Humectants, Emollients), Medication (Topical Steroid, Antihistamines Agents, Immune modulator, Others)), Route of Administration (Oral, To...
$ 3750
Sangers Sequencing Service Comprehensive Study by Application (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Forensics, Other), Laboratory (Web Lab, Dry Lab), Servic...
$ 3750
Surgical Slush Units Comprehensive Study by Type (Basin-based, Container-based), Application (Ambulatory Surgery Centers, Hospitals, Trauma Centers, Others), Procedure (Transplant Surgical Procedures...
$ 3650
Veterinary Stereotactic Radiosurgery Comprehensive Study by Type (Gamma Knife, Linear Accelerator, Particle Beam Radiation therapy, Cyber Knife), Application (Veterinary Hospitals, Veterinary Clinics...
$ 3650
Prescription Delivery Services Comprehensive Study by Type (Therapeutic Drugs, Diabetes Drugs, Cholesterol Disorders Drugs, Wellness Supplements, OTC Drugs, Diagnostic Kits, Others), Delivery Type (P...
$ 3450
Peri implantitis Comprehensive Study by Type (Non-surgical treatment, Surgical treatment), Therapy Class (Class-1, Classs-2, Class-3, Class-4), Severity (Early(PD>=4mm), Moderate(PD>=6mm), Advanced(P...
$ 3350